Nanfang pharmaceutical a new type of new targeted nano Paclitaxel injection (Xinsu) is expected to complete preclinical research in 2017

"Xinsu" is a new anti-cancer drug developed by Nanfang pharmaceutical last year R & D is divided into six stages, and now it has entered the third stage " On May 10, Li Yong, deputy general manager of Fujian Nanfang Pharmaceutical Co., Ltd., talked about the progress of the world's first new drug "Xinsu" The total investment of the R & D project is 60 million yuan, and 10 million yuan has been invested at present The medical name of "Xinsu" is "new targeted nano Paclitaxel Injection" It is a new injection developed independently by Nanfang pharmaceutical company, which combines modern polymer micelle technology with paclitaxel, an anti-tumor drug The drug is different from the traditional Paclitaxel injection It is superior to the traditional injection in the aspects of targeting, anti multidrug resistance, reducing toxicity and increasing efficiency, and improving human immunity The nano micelles of ginsenoside can be used not only in paclitaxel, but also in other insoluble anti-tumor drugs, as well as in cardio cerebral vascular, traditional Chinese medicine injection and other broader pharmaceutical fields Since its introduction to the market, Mingxi taxol has occupied 30% of the international market, but the products are all APIs After the completion of the development of "Xinsu", it will be applied for the national first-class new drugs, which will bring great breakthroughs in both economic and social benefits With the support of the Mingxi County Party committee and the county government, the research on "Xinsu" is progressing smoothly At present, the company has cooperated with Macao University of science and technology and Fujian Medical University to complete the research of liquid stability, micelle particle size, micelle encapsulation rate, etc the preparation of the drug and its compounds have also completed the patent application at home and abroad It is expected to complete the pre clinical research and pre clinical approval acceptance in 2017.